Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL

In English

Författare

  • Alisa M. Goldstein
  • May Chan
  • Mark Harland
  • Elizabeth M. Gillanders
  • Nicholas K. Hayward
  • Marie-Francoise Avril
  • Esther Azizi
  • Giovanna Bianchi-Scarra
  • D. Timothy Bishop
  • Brigitte Bressac-de Paillerets
  • William Bruno
  • Donato Calista
  • Lisa A. Cannon Albright
  • Florence Demenais
  • David E. Elder
  • Paola Ghiorzo
  • Nelleke A. Gruis
  • Johan Hansson
  • David Hogg
  • Elizabeth A. Holland
  • Peter A. Kanetsky
  • Richard F. Kefford
  • Maria Teresa Landi
  • Julie Lang
  • Sancy A. Leachman
  • Rona M. MacKie
  • Veronica Magnusson
  • Graham J. Mann
  • Kristin Niendorf
  • Julia Newton Bishop
  • Jane M. Palmer
  • Susana Puig
  • Joan A. Puig-Butille
  • Femke A. de Snoo
  • Mitchell Stark
  • Hensin Tsao
  • Margaret A. Tucker
  • Linda Whitaker
  • Emanuel Yakobson
  • Åke Borg
  • Håkan Olsson
Visa allt

Summary, in English

GenoMEL, comprising major familial melanoma research groups from North America, Europe, Asia, and Australia has created the largest familial melanoma sample yet available to characterize mutations in the high-risk melanoma susceptibility genes CDKN2A/alternate reading frames (ARF), which encodes p16 and p14ARF, and CDK4 and to evaluate their relationship with pancreatic cancer (PC), neural system tumors (NST), and uveal melanoma (UM). This study included 466 families (2,137 patients) with at least three melanoma patients from 17 GenoMEL centers. Overall, 41% (n = 190) of families had mutations; most involved p16 (n = 178). Mutations in CDK4 (n = 5) and ARF (n = 7) occurred at similar frequencies (2-3%). There were striking differences in mutations across geographic locales. The proportion of families with the most frequent founder mutation(s) of each locale differed significantly across the seven regions (P = 0.0009). Single founder CDKN2A mutations were predominant in Sweden (p.R112_L113insR, 92% of family's mutations) and the Netherlands (c.225_243del19, 90% of family's mutations). France, Spain, and Italy had the same most frequent mutation (p.G101W). Similarly, Australia and United Kingdom had the same most common mutations (p.M53I, cdVS2-105A > G, p.R24P, and p.L32P). As reported previously, there was a strong association between PC and CDKN2A mutations (P < 0.0001). This relationship differed by mutation. In contrast, there was little evidence for an association between CDKN2A mutations and NST (P = 0.52) or UM (P = 0.25). There was a marginally significant association between NST and ARF (P = 0.05). However, this particular evaluation had low power and requires confirmation. This GenoMEL study provides the most extensive characterization of mutations in high-risk melanoma susceptibility genes in families with three or more melanoma patients yet available.

Publiceringsår

2006

Språk

Engelska

Sidor

9818-9828

Publikation/Tidskrift/Serie

Cancer Research

Volym

66

Issue

20

Dokumenttyp

Artikel i tidskrift

Förlag

American Association for Cancer Research Inc.

Ämne

  • Cancer and Oncology

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1538-7445